Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis

Recruiting now

Conditions studied: Cardiac Amyloidosis

In brief

Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).

Key facts

Study ID

NCT07154381

Run by

University Hospital, Essen

People needed

25

Starts

2019-12-09

Expected to finish

2025-12-01

Last updated by the study team

2025-09-04

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 40 years
• proven Amyloidosis (ATTR or AL)
• Women: negative pregnancy test less than weeks prior imaging.

You may not qualify if…

• Patients receiving amyloidosis-specific treatment prior study inclusion.
• Patients participating in other clinical trails for treatment of Amyloidosis.
• Pregnancy
• Contraindiactions for MRI (eGFR<30ml/min/1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).
• inability of consent
• Refusal of consent

Where it is running

• Department of Nuclear medicine, University Hospital Essen — Essen, North Rhine-Westphalia, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.